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Abstract  
Background: Mucous membrane pemphigoid (MMP) is a rare, chronic, and often aggressive 
subepidermal autoimmune blistering disease potentially affecting several mucous membranes 
with blisters and secondary erosions and scars. The pathogenesis of MMP is poorly understood, 
and the contribution of genetic predispositions, other than HLA class II allele variants to MMP, is 
unknown.  
Objectives: The objective of this study is to identify susceptibility genes for MMP in a British 
cohort of MMP patients. 
Methods: A GWAS was conducted in a British cohort of 106 MMP patients. Publicly available 
genotypes of 2,900 blood donors of the UK Blood Service and of 6,740 individuals of the 1958 
British Birth Cohort served as control. Subsequently, putative susceptibility genes were 
independently replicated in a German cohort of 42 MMP patients.  
Results: The GWAS found 38 SNPs in 28 haploblocks with an odds ratio >2 reaching genome-
wide significance (p<5.7x10-7). Replication confirmed an association of MMP with SNPs in 
rs17203398 (OR: 3.9), located intronically in the β-galactocerebrosidase gene (GALC) on 
chromosome 14, and with recessive polymorphisms in rs9936045 (OR: 3.1) in the intergenic 
region between CASC16 and CHD9 on chromosome 16.  
Conclusions: The risk of developing MMP is partially genetically determined. SNPs in GALC 
enhance the risk for MMP, indicating that β-galactocerebrosidase may be involved in the 
pathogenesis of MMP. Likewise, impacts of polymorphisms in the intergenic region between 
CASC16 and CHD9 on the activity of neighboring genes may facilitate the emergence of MMP. 
The putative role of both polymorphisms requires functional studies in the future.  
 
Keywords: Susceptibility genes, inflammation, fibrosis   
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Introduction 
Pemphigoid diseases are a group of seven different subepidermal autoimmune blistering 
diseases driven by autoantibodies directed to proteins of the dermal-epidermal anchoring 
complex (1). They affect the skin and mucous membranes to a variable extent depending on the 
specific disease and the individual patient. Mucous membrane pemphigoid (MMP), formerly 
known as “cicatricial pemphigoid”, is the only pemphigoid disease predominantly affecting 
mucous membranes, not the skin. Mucous membranes, which can be affected by the disease, 
are that of the conjunctivae, the oral cavity, the esophagus, the nose, the pharynx, the larynx, 
the trachea, the anal canal, and the genitalia (2, 3). Disease can simultaneously afflict all these 
mucous membranes or can be locally restricted to specific surfaces. Frequently, MMP only 
affects the conjunctiva or the oral cavity and is then designated as ocular and oral pemphigoid, 
respectively (3). MMP lesions, except for those in the oral cavity, usually scar. The scarring may 
result in impaired organ function and lead to organ failure. Typical residual states in MMP 
patients include strictures in the upper digestive, airway and anogenital tracts, as well as 
conjunctival scarring causing severe dry eye, ingrowing lashes, and corneal stem cell failure, all 
of which result in corneal opacification and blindness. To prevent the emergence of these 
debilitating residual states, MMP is usually treated aggressively upon diagnosis with potent, 
immunosuppressive drugs (2, 4).  
The pathogenesis of MMP is still largely unknown, but it is thought to be driven by IgG and/or 
IgA autoantibodies directed against different proteins of the dermal-epidermal anchoring 
complex, including BP180, BP230, β4 integrin, laminin 332 (laminin 5), and type VII collagen (2). 
Notably, autoantibodies against only one of these antigens are sufficient to induce disease (5). 
The most frequent autoantigen in MMP is BP180 with 75% of patients producing IgG 
autoantibodies against it (5). BP180 is also the only major autoantigen in bullous pemphigoid 
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and pemphigoid gestationis (1, 6), illustrating the close relationship between MMP and these 
two other pemphigoid diseases. 
Binding of MMP autoantibodies to the dermal-epidermal junction initiates effector cell 
recruitment by still unidentified mechanisms. Thus, in acute disease, the histopathology of MMP 
lesions feature subepidermal infiltration predominantly by neutrophils, T cells and eosinophils. 
Products of these effector cells, such as proteases and radical oxygen species, are presumably 
responsible for the disruption of dermal-epidermal adhesion resulting in mucosal blistering (7-9). 
In addition, the induction of a profibrotic phenotype in fibroblasts, which consequently leads to 
severe scarring, is pivotal for the pathogenesis of MMP (10). Inflammation and scarring are 
mediated by neutrophils, dendritic cells, mast cells, eosinophils, macrophages and T cells. 
These effects are mediated by their cytokines IL-2, IL-4, IL-5, IL-13, IFN (interferon gamma) 
and the growth factors TNF (tumour necrosis factor alpha), PDGF (platelet derived growth 
factor), TGF (transforming growth factor beta) and HSP47 (heat shock protein). ALDH/RA 
(aldehyde dehydrogenase/retinoic acid)-mediated paracrine and autocrine effects initiate and 
perpetuate fibroblast activation which persists after control of inflammation (11).  
Notably, in contrast to most other autoimmune diseases, only very little is known about 
individual predispositions for pemphigoid diseases in general as well as for MMP specifically. 
One major reason for this situation is the low prevalence of pemphigoid diseases, with MMP, 
e.g., occurring with a prevalence as low as 24 per million in Germany (12), and the consequent 
lack of genome-wide association studies (GWAS). To date susceptibility to MMP has only been 
associated with three genetic variants of the HLA class II alleles: DQB1*0301, DRB*04, and 
DRB*11 (5, 13-19). However, whether other genetic polymorphisms, outside the HLA class II 
locus impact the susceptibility to MMP has been unknown. We therefore performed a GWAS in 
a cohort of MMP patients and identified 38 SNPs in 28 haploblocks associated with MMP. 
Replication subsequently corroborated an association of MMP with polymorphisms in GALC, the 
 6 
gene encoding for β-galactocerebrosidase (EC 3.2.1.46). GALC has not previously been 
implicated in the pathogenesis of MMP or other pemphigoid diseases.  
 
Patients and Methods 
Study population 
For the GWAS, 106 patients (Males: 56; females: 50; age: 18 – 86 years) suffering from MMP 
were recruited at the Moorfields Eye Hospital (London, UK). The diagnosis of MMP was based 
on the clinical presentation and a positive finding by direct immunofluorescence (IF) microscopy 
or typical clinical presentation with MMP autoantibodies detectable in the serum and exclusion 
of other causes of scarring conjunctivitis, as previously described (20, 21). Clinical data on MMP 
patients were collected using a case report form asking patients to list all body sites presently or 
previously affected by MMP lesions. Sites, which exhibited signs of MMP in the past, were 
classified “affected” irrespective of the current state of disease activity or of the presence or 
absence of residuals. In addition, patients were clinically examined for signs of MMP at all 
potential anatomical sites except for the oesophagus, by ophthalmologists, dermatologists, oral 
medicine specialists, and otolaryngologists. 45 individuals (22 males; 23 females; age: 18 - 83 
years), who were having surgery for ocular conditions, without associated systemic disease, 
including cataract, squint, retinal detachment, Fuchs’ corneal dystrophy, keratoconus, and 
blepharoplasty, as well as the publicly available genotypes of 2,900 blood donors of the UK 
Blood Service and of 6,740 individuals of the 1958 British Birth Cohort served as controls. 
Clinical information on the British cohort are summarized in tables S1 and S2. For replication, a 
cohort of 42 MMP patients was recruited in Dermatology Departments of University Hospitals in 
Germany. MMP diagnosis was based on the same criteria, as described above. Clinical 
information on the German cohort are summarized in table S3. 250 age- and sex-matched 
controls were provided by the Popgen Biobank (Kiel, Germany). The study was approved by the 
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Moorfields & Whittington research ethics committee (reference number: 09/H0721/54) and the 
ethic committee of the University of Lübeck (reference number: 08-156). 
 
Genome-wide association study (GWAS) 
Genomic DNA of the MMP patient cohort and the internal controls was isolated from whole 
blood. Genome-wide genotyping was executed using the Illumina Immunochip Array (Illumina, 
San Diego, CA, USA) according to the manufacturer’s instructions. 9,684 samples addressing 
196,524 SNPs were genotyped and initially included in this study. Quality control and GWAS 
analysis of genotyped single nucleotide polymorphism (SNPs) were performed using the 
software programs GenomeStudio (Illumina), PLINK version 1.07 (22), and R. Comparing 
internal and public controls, 59,527 SNPs had significantly different genotype distributions (p < 
0.01), when applying a logistic regression analysis in PLINK, and were subsequently excluded 
from further analysis. The remaining SNPs were quality-checked. R was used to exclude SNPs 
from further analysis when exhibiting a call rate < 99% or a 10% GC-Score < 0.8*90th percentile, 
as recommended by Illumina. In addition, using PLINK, SNPs were also excluded if more than 
10% of genotypes were missing, if the deviation of Hardy-Weinberg equilibrium was significant 
(pHWE < 10-5), or if the minor allele frequency (MAF) was < 2.5%. After this additional quality 
check, 88,065 SNPs remained for comparison between MMP patients and controls with 95 
MMP patients and 9,646 control samples left for analyses. These SNPs and samples were 
analyzed for association via logistic regression with the first five principal-components as 
covariates. Principal component analysis was performed using EIGENSOFT version 5.0.2 (23). 
In this analysis, sex was not considered as covariate due to missing information. A global 
significance of p < 5 x 10-8 was defined as statistically significant and an odds ratio > 2 was 
considered biologically relevant. 
 
Replication  
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DNA for replication was isolated using standard extraction kits (Qiagen, Hilden, Germany). 
Replication was conducted using the TaqMan® SNP Genotyping Assay (Applied Biosystems, 
Carlsbad, CA, USA) according to the manufacturer’s instructions applying unlabeled forward 
and reverse PCR primers in combination with VIC® dye – MGB probes for detection of the Allele 
1 sequence and 6-FAM™ dye – MGB probes for the detection of the Allele 2 sequence (Suppl. 
Tabl. S1). The qPCR was run on the realplex Mastercycler (Eppendorf, Hamburg, Germany) 
with an initiation of 10 min at 95 °C and 40 cycles each of 15 sec at 95°C annealing temperature 
followed by 1 min at 60 °C for elongation. Samples that repetitively did not yield unambiguous 
genotypes were excluded from further analysis. Replication results of the MMP patient and the 
control groups were analyzed for statistical significance by Chi-square test, testing for both 
overall significance, and significance in a dominant or recessive setting for the distinct minor 
allele. In either case, p < 0.05 was regarded as statistically significant. 
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Results 
We conducted a GWAS on 95 MMP samples and 9,646 control samples comparing the 
frequency of 88,065 SNPs in these two groups. This analysis yielded 38 SNPs in 28 
haploblocks with an odds ratio > 2 reaching the genome-wide significance level of p < 5.7 x 10-7 
in the analysis with and without 5 principal components as covariates (Fig. 1). These 38 SNPs 
and their precise location are listed in Table 1. They were scattered over 12 autosomal 
chromosomes. In addition to these 38 SNPs, our analysis also illustrated the strong association 
of susceptibility to MMP with certain HLA haplotypes, which was reflected by a distinct peak at 
the site of this the HLA locus on chromosome 6 in the Manhattan plot (Fig. 1). This finding 
confirms the validity of our approach. The mean odds ratio of these 38 SNPs for disease was 
2.6; the highest odds ratio was 3.9 and was linked to 1kg_14_87519600 on chromosome 14 
(Tab. S4).  
To select the most promising genes for replication, we conducted an association analysis 
factoring in SNPs with higher p-values located in the proximity of the 38 identified SNPs. Thus, 
we exploited the fact that in the vicinity of SNPs of high pathogenic relevance, other SNPs are 
frequently detected (Fig. 2). By this strategy, those 6 SNPs most likely pathogenetically relevant 
among the 38 disease-associated SNPs were singled out for replication. In the replication 
analysis, the frequency distribution between controls and MMP patients for 2 of these 6 SNPs, 
precisely for the SNPs 1kg_14_87519600 and rs9936045, was statistically significantly different 
(Tab. 1). Herein, the frequency of the SNP 1kg_14_87519600 (rs17203398) was not only 
statistically significantly different between the two groups when the general significance (p = 
0.004) was evaluated, but also when the recessive (p = 0.003) and the dominant (p = 0.011) 
model were examined (Tab. 1). rs17203398 is located on chromosome 14 in the intron region of 
the gene GALC. The differences for the SNP rs9936045 was in contrast only significantly 
different in the recessive model (p = 0.022). rs9936045 is located on chromosome 16 between 
the genes CASC16 and CHD9. 
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Discussion 
Although individual genetic predispositions are in general considered to play a major role in the 
pathogenesis of autoimmune diseases and a plethora of different polymorphisms of most 
diverse genes has been identified to modulate susceptibility to autoimmunity, genetic 
predispositions for pemphigoid diseases, including MMP, are almost completely unknown. 
Therefore, we set out to conduct the first GWAS for MMP in a British cohort of 106 MMP 
patients. This study yielded 38 SNPs associated with the occurrence of MMP, suggesting that, 
as in other autoimmune diseases, polymorphisms in genes other than HLA class II alleles 
additionally co-determine the individual susceptibility to MMP.  
Replication of 6 of these genes identified in the GWAS corroborated the association between 
SNPs in GALC and in a region between the genes CASC16 and CHD9 with MMP. Both loci 
have not previously been implicated in the pathogenesis of MMP or in any other pemphigoid 
disease, although polymorphisms in GALC were previously associated with susceptibility to 
inflammatory bowel disease (24, 25).  
GALC encodes the lysosomal enzyme β-galactocerebrosidase (EC 3.2.1.46), which is 
expressed in most tissues and is critically involved in the regulation of cellular sphingolipids (26, 
27). Homozygous deletion of GALC causes Krabbe disease (globoid cell leukodystrophy), an 
autosomal-recessive hereditary disorder, featuring multiple neurodegenerative deficits due to 
diffuse demyelination in the peripheral and central nervous system (28). β-galactocerebrosidase 
is also involved in cancer cell metabolism, primary open-angle glaucoma, and in the regulation 
of the hematopoietic stem cell niche (29-31). Its expression in cancer cells blocks apoptosis with 
β-galactocerebrosidase shifting the balance between the proapoptotic sphingolipid ceramide 
towards its antiapoptotic derivative galactosylcerebroside (29). The regulation of sphingolipid 
levels is also pivotal to maintain the hematopoietic stem cell niche. Thus, functional deficiency in 
β-galactocerebrosidase decreases proliferation of early progenitor cells in mice (31).  
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Intriguingly, hyperreactive immune responses were identified in the last decade as symptom 
in several lysosomal storage diseases, including Krabbe disease, and have also been 
suggested to significantly contribute to the emergence of the neurological hallmark symptoms of 
these diseases (32). Thus, lymphocytes and monocytes of Krabbe disease patients exhibit a 
proinflammatory activation state characterized, amongst others, by an increased release of 
TNF-α upon stimulation (33). Furthermore, in Twitcher mice, a mouse model of Krabbe disease, 
expression of proinflammatory cytokines and chemokines is enhanced and contributes to 
disease pathogenesis (34, 35).  
Through these immunoregulatory functions, aberrant β-galactocerebrosidase activity may 
also directly contribute to the pathogenesis of autoimmune diseases, such as MMP. With TNF-α 
levels elevated in MMP patients and its inhibition effective in treating the disease, it is tempting 
to speculate that GALC polymorphisms may elevate TNF-α levels predisposing to the 
development of MMP. In line with this hypothesis, TNF-α induces the release of proinflammatory 
mediators from conjunctival fibroblasts, which can in turn promote conjunctival fibrosis. 
Heterozygous deletions of GALC are also a significant risk factor for primary open-angle 
glaucoma. Although the pathogenic mechanism behind this association has not been 
elucidated, this association suggests that physiological functions of β-galactocerebrosidase are 
partially gene copy number-sensitive and that heterozygous mutations of GALC are already 
sufficient to disturb organ homeostasis (30).  
The second SNP associated with MMP was rs9936045, which is located on chromosome 16 
in the intergenic region between CASC16 and CHD9. The significance of this finding and 
whether the polymorphism impacts the activity of the two neighboring genes is currently unclear. 
In addition, the function of these two neighboring genes is poorly understood, thus complicating 
its clarification. The biological function of Cancer susceptibility candidate 16 (CASC16; also 
designated as “LINC00918” or “LOC643714”), the gene located on the reverse strand upstream 
of rs9936045, has not been characterized, but polymorphisms of the gene have been 
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associated with the risk for breast and lung cancer (36-39). CHD9, the gene downstream of 
rs9936045, encodes the protein “chromodomain helicase DNA binding protein 9” (CHD9), which 
has also been referred to as “Chromatin Related Mesenchymal Modulator” (CReMM) and 
“PPARα-interacting cofactor 320” (PRIC320). CHD9 is a transcription coactivator with DNA 
helicase activity. Thus, the protein bears both chromatin remodeling and nuclear receptor 
coactivation functions and serves as coactivator of several transcription factors, including 
PPAR-α, CAR, ERα, RXR, CBP, PRIP, and PBP (40-42), suggesting a wide array of possible 
regulatory roles for this protein. However, except for a role in osteogenic differentiation (41, 43), 
the physiological roles of CHD9 are still largely elusive.  
The only gene polymorphism outside the HLA class II locus previously associated with MMP 
is the IL-4RA-1902 SNP in a Northern Italian cohort of 41 MMP patients suffering from oral 
pemphigoid (44). However, the pathogenic relevance of this polymorphism has not been 
addressed. Carriers of this polymorphism exhibit an attenuated response to IL-4 cell stimulation. 
As IL-4 exerts profibrotic effects in MMP and oral pemphigoid is the only subtype of MMP 
typically not developing scarring (45). In our study, focusing on ocular MMP, we did not find an 
association between the IL-4RA-1902 SNP and MMP. The association of this polymorphism to 
MMP may therefore be limited to oral pemphigoid. 
Bullous pemphigoid (BP) is the disease most closely related to MMP. Both diseases share 
BP180 and BP230 as common autoantigens, and in 20% of BP patients blisters and erosions 
on mucous membranes emerge (2). Thus, the two diseases are sometimes hard to distinguish 
and may transform from one to the other. Like in MMP, there is also still a paucity in the 
identification of gene polymorphisms predisposing to BP. Susceptibility to BP has been 
associated with SNPs in IL1B, the gene for IL-1β, in a Chinese cohort and in CYP2D6, the gene 
for the cytochrome P450 oxidase 2D6, in a Polish cohort (46, 47). In addition, copy number 
variations (CNVs) in the Fcγ receptor genes FCGR2B and FCGR3B as well as polymorphisms 
in the mitochondrial gene ATP8 have been associated with the risk for BP in a German cohort 
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(48, 49). While our study design did not allow examining the effect of CNVs or mitochondrial 
genes to MMP, it could have detected associations to IL1B and CYP2D6 SNPs. The fact that 
both genes are not among the list of the 49 genes identified in our study suggests that despite 
the resemblance of the two diseases, genetic predispositions for the two diseases significantly 
differ. 
In sum, this first GWAS in MMP patients identified two gene loci, which had not previously 
been implicated in autoantibody-driven autoimmune diseases, including pemphigoid diseases. 
Future studies will address the functional relevance of these polymorphisms for the 
pathogenesis of MMP. Our findings illustrate that MMP must be considered a complex, 
multifactorial disease with a previously underappreciated significant contribution of genes 
outside the HLA locus to the pathogenesis of disease. 
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Table 1: Replication analysis for 6 selected SNPs 
SNP, single nucleotide polymorphism; Chr, chromosome; BP, base pair number; OR, odd ratio 
  
SNP Chr BP 
Minor 
allele 
OR 
Significance 
(p) 
Dominant 
model (p) 
Recessive 
model (p) 
Closest 
gene(s) 
imm_1_181612330 1 181612330 T 2.6 0.280 0.074 0.959 NMNAT2 
seq-rs523937 2 219145840 G 2.5 0.999 0.707 0.381 RQCD1 
1kg_14_87519600 14 87519600 C 3.9 0.004 0.011 0.003 GALC 
rs9936045 16 51472905 G 3.1 0.599 0.175 0.022 
CASC16/CH
D9 
seq-rs1043680 19 60204159 C 2.9 0.581 0.517 0.816 NLRP2 
seq-rs4806637 19 60247800 G 2.8 0.669 0.955 n/a RDH13 
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Figure 1. Manhattan plot of a genome-wide association study in 95 MMP patients and 
9,646 control samples. The ordinate displays the -log10 P values of 88,065 SNPs included in 
this study, and the abscissa shows the chromosomal positions. The horizontal blue line 
represents the reaching the genome-wide significance level of p < 5 x 10-8. 38 SNPs were 
above this cut-off and were considered biologically relevant when achieving an odds ratio of > 2.  
 
Figure 2. Detailed view of the four loci most closely associated with MMP. The associated 
regions are located on (A) Chr. 1, (B) Chr. 2, (C) Chr. 16, (D) Chr. 19. The −log10 p values of the 
genotyped SNPs (left ordinate) and the regional recombination rate (right ordinate) are plotted 
against their physical position on the chromosomes. In each plot, the solid diamond represents 
the top-ranked SNP in the region. 
 
Table 1. Replication analysis for 6 selected SNPs. Replication was conducted in a German 
MMP cohort and controls using qPCR. Both groups were tested for statistically significant 
differences by Χ2-test and were tested for overall significance, as well as for significance in a 
dominant or recessive setting for the minor allele. p < 0.05 was regarded as statistically 
significant. Significant differences are in bold. 
 
